Western University

Scholarship@Western
Paediatrics Publications

Paediatrics Department

12-1-2017

Treatment with AICAR inhibits blastocyst development,
trophectodermdifferentiation and tight junction formation and
function in mice
Michele D. Calder
Western University

Nicole A. Edwards
Western University

Dean H. Betts
Western University, dean.betts@schulich.uwo.ca

Andrew J. Watson
Western University

Follow this and additional works at: https://ir.lib.uwo.ca/paedpub

Citation of this paper:
Calder, Michele D.; Edwards, Nicole A.; Betts, Dean H.; and Watson, Andrew J., "Treatment with AICAR
inhibits blastocyst development, trophectodermdifferentiation and tight junction formation and function in
mice" (2017). Paediatrics Publications. 819.
https://ir.lib.uwo.ca/paedpub/819

Molecular Human Reproduction, Vol.23, No.11 pp. 771–785, 2017
Advanced Access publication on September 28, 2017 doi:10.1093/molehr/gax050

ORIGINAL ARTICLE

Michele D. Calder1,2,*, Nicole A. Edwards1, Dean H. Betts1,2,3,
and Andrew J. Watson1,2,3
1

Departments of Physiology and Pharmacology, Western University, London, Ontario, Canada 2Obstetrics and Gynaecology, Schulich
School of Medicine, Western University, London, Ontario, Canada 3Children’s Health Research Institute (CHRI), Lawson Health Research
Institute (LHRI), London, Ontario, Canada
*Correspondence address. Dental Sciences Rm. 00066; Medical Science Building, 1151 Richmond St. N, London, Ontario, Canada.
Tel: +1-519-661-2111×86925; Fax: +1-519-661-3827; E-mail: Michele.Calder@schulich.uwo.ca

Submitted on October 7, 2016; resubmitted on August 18, 2017; editorial decision on August 30, 2017; accepted on September 6, 2017

STUDY QUESTION: What is the impact of adenosine monophosphate-activated protein kinase (AMPK) activation on blastocyst formation, gene expression, and tight junction formation and function?
SUMMARY ANSWER: AMPK activity must be tightly controlled for normal preimplantation development and blastocyst formation

to occur.
WHAT IS KNOWN ALREADY: AMPK isoforms are detectable in oocytes, cumulus cells and preimplantation embryos. Cultured

embryos are subject to many stresses that can activate AMPK.
STUDY DESIGN, SIZE, DURATION: Two primary experiments were carried out to determine the effect of AICAR treatment on

embryo development and maintenance of the blastocoel cavity. Embryos were recovered from superovulated mice. First, 2-cell embryos
were treated with a concentration series (0–2000 μM) of AICAR for 48 h until blastocyst formation would normally occur. In the second
experiment, expanded mouse blastocysts were treated for 9 h with 1000 μM AICAR.
PARTICIPANTS/MATERIALS, SETTING, METHODS: Outcomes measured included development to the blastocyst stage, cell number, blastocyst volume, AMPK phosphorylation, Cdx2 and blastocyst formation gene family expression (mRNAs and protein measured using
quantitative RT-PCR, immunoblotting, immunoﬂuorescence), tight junction function (FITC dextran dye uptake assay), and blastocyst ATP
levels. The reversibility of AICAR treatment was assessed using Compound C (CC), a well-known inhibitor of AMPK, alone or in combination
with AICAR.
MAIN RESULTS AND THE ROLE OF CHANCE: Prolonged treatment with AICAR from the 2-cell stage onward decreases blastocyst

formation, reduces total cell number, embryo diameter, leads to loss of trophectoderm cell contacts and membrane zona occludens-1 staining, and increased nuclear condensation. Treatment with CC alone inhibited blastocyst development only at concentrations that are higher
than normally used. AICAR treated embryos displayed altered mRNA and protein levels of blastocyst formation genes. Treatment of blastocysts with AICAR for 9 h induced blastocyst collapse, altered blastocyst formation gene expression, increased tight junction permeability and
decreased CDX2. Treated blastocysts displayed three phenotypes: those that were unaffected by treatment, those in which treatment was
reversible, and those in which effects were irreversible.
LARGE SCALE DATA: Not applicable.
LIMITATIONS, REASONS FOR CAUTION: Our study investigates the effects of AICAR treatment on early development. While

AICAR does increase AMPK activity and this is demonstrated in our study, AICAR is not a natural regulator of AMPK activity and some
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outcomes may result from off target non-AMPK AICAR regulated events. To support our results, blastocyst developmental outcomes were
conﬁrmed with two other well-known small molecule activators of AMPK, metformin and phenformin.
WIDER IMPLICATIONS OF THE FINDINGS: Metformin, an AMPK activator, is widely used to treat type II diabetes and polycystic
ovarian disorder (PCOS). Our results indicate that early embryonic AMPK levels must be tightly regulated to ensure normal preimplantation
development. Thus, use of metformin should be carefully considered during preimplantation and early post-embryo transfer phases of fertility
treatment cycles.
STUDY FUNDING AND COMPETING INTEREST(S): Canadian Institutes of Health Research (CIHR) operating funds. There are no

competing interests.
Key words: AMPK / stress pathways / embryo culture / assisted reproductive technologies / preimplantation / blastocyst formation

In mammals, preimplantation development begins at fertilization and
ends with the formation of the ﬂuid-ﬁlled blastocyst, which hatches
from the zona pellucida and implants in the uterine wall to establish a
pregnancy (MacPhee et al., 2000; Watson et al., 2004). The early
blastocyst consists of two cell types: the inner cell mass (ICM) and the
trophectoderm (TE) (Watson et al., 2004). The ICM at this stage is
composed of undifferentiated cells that later will become the embryo
proper. The TE mediates implantation into the uterus and becomes
the embryonic part of the placenta. The TE is characterized by the
expression of early transcription factors such as caudal homeobox two
(CDX2, Strumpf et al., 2005). Tight junctions (TJ), containing zona
occludens-1 (ZO-1, TJP1) and occludin (OCLN), form a seal between
TE cells, which is critical for ﬂuid accumulation within the blastocyst
cavity (Fleming et al., 1989; Kim et al., 2004; Violette et al., 2006; Bell
and Watson, 2013). The activity of the Na+/K+ ATPase establishes
an ionic gradient that drives ﬂuid accumulation in the cavity, and regulates TE tight junction development and function (Betts et al., 1998;
Violette et al., 2006; Madan et al., 2007). ATPase Na+/K+ transporting subunit beta 1 (Atp1b1) knockdowns are embryonic lethal, as
embryos arrest at the morula stage (Madan et al., 2007). In addition,
aquaporins (AQP) are localized to the TE membrane and facilitate
water movement into the blastocyst cavity (Barcroft et al., 2003).
Other important genes that may measure preimplantation embryo
developmental competence are those involved with embryonic arrest.
Growth arrest DNA damage-inducible alpha (GADD45A) is involved
in cell cycle arrest when there is DNA damage, to give time to repair
the damage (reviewed in Zhan, 2005).
A gene critical for the embryonic response to environmental
changes is adenosine monophosphate-activated protein kinase
(AMPK). AMPK is a master regulator of cellular glucose and lipid metabolism (reviewed in Hardie et al., 2012). Phosphorylation of AMPK
activates catabolic pathways to generate ATP (i.e. fatty acid oxidation
and glycolysis) and shuts down anabolic pathways to conserve energy
(i.e. lipo-, sterol- and gluconeogenesis) (Corton et al., 1995; Zhou
et al., 2001; Hardie, 2011; Hardie et al., 2012). The signaling cascades
can result in phosphorylation of acetyl CoA carboxylase (ACC), which
would inactivate lipid synthesis (Carling et al., 1989), and therefore
phosphorylated ACC is commonly used as a marker of AMPK activation (Zhou et al., 2001). AMPK is activated when the ratio of AMP/
ATP changes, or as a result of hormones, hypo- or hyperglycemia,
hyperosmolarity, exercise and oxidative stress (Hardie et al., 2012).
AMPK phosphorylation and activity can be decreased in cultured cells

by exposure to high glucose concentrations (da Silva Xavier et al.,
2000) and is decreased in diabetes and obesity (Liu et al., 2006; Blume
et al., 2007). Metformin is a commonly used oral diabetes drug which
increases activation of AMPK (Zhou et al., 2001). Metformin is widely
used in infertile women to treat insulin resistance due to polycystic
ovarian syndrome (PCOS), to restore spontaneous ovulatory cycles
(Nestler et al., 1998), or to improve response to other ART therapies
(Nestler et al., 1998; Tang et al., 2006; Palomba et al., 2014). In cultured cells, AICAR (5-aminoimidazole-4-carboxamide ribonucleotide)
is often used to activate AMPK as it is metabolized to an AMP mimetic,
resulting in unchanged ATP levels (Corton et al., 1995; Zhou et al.,
2001) Frequently used experimental concentrations of AICAR range
from 0.5 to 2 mM (Chen et al., 2006; Guo et al., 2009). AICAR and
metformin have similar effects on AMPK and targets (Zhou et al.,
2001; Blume et al., 2007). Compound C (CC) is an AMPK inhibitor
that competes for binding with ATP (Zhou et al., 2001) and is typically
used at concentrations between 5 and 20 μM (Zhou et al., 2001; Chen
et al., 2006; Xie et al., 2013). In addition, AICAR and metformin have
AMPK-independent effects (Guo et al., 2009; Liu et al., 2014). One of
these effects may be the regulation of the mTOR pathway, resulting in
the reduced phosphorylation of ribosomal protein S6 (Guo et al.,
2009; Klubo-Gwiezdzinska et al., 2012).
AMPK is composed of a heterotrimer of α, β and γ subunits
(reviewed in Hardie, 2011). The catalytic subunits of AMPK (α1 and
α2, PRKAA1 and PRKAA2) are encoded by separate genes and both
proteins are detectable in oocytes and cumulus cells (Downs et al.,
2002). β and γ subunit mRNAs are also expressed in cumulus and
oocytes (Mayes et al., 2007). Activation of AMPK improves meiosis of
mouse oocytes cultured under inhibitory conditions (Downs et al.,
2002). However, activation of AMPK with either AICAR or metformin
has the opposite effect in bovine and porcine cumulus-oocyte complexes and delays maturation (Mayes et al., 2007; Tosca et al., 2007;
Bilodeau-Goeseels et al., 2011, 2014). Knockout of individual PRKA
isoforms in mice does not seem to produce reproductive phenotypes
in vivo. However, oocyte-speciﬁc protein kinase AMP-activated catalytic subunit alpha 1 (Prkaa1) knockout reduced in vitro mouse embryo
development (Bertoldo et al., 2015), and this may be due to higher
stress imposed on cultured embryos. Embryos cultured in vitro are
exposed to many stresses such as hyperosmolarity, variations in temperature, pH, oxygen, metabolic substrate concentrations, light exposure and pipetting (Xie et al., 2007; Wale and Gardner, 2016). Stresses
such as hyperosmolarity can activate AMPK in embryos, embryonic
stem cells, and trophoblast stem cells, and can induce the differentiation of trophoblast stem cells (Zhong et al., 2010). Activators of
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Materials and Methods
Mouse embryos collection and culture
Three to four-week-old female CD-1 mice and adult male CD-1 mice
(4–8 months) were obtained from Charles River, Canada. Females were
injected with 7.5 IU pregnant mare serum gonadotrophin (PMSG; Folligon,
Intervet, Whitby, ON) to stimulate follicular development, followed by 7.5
IU human chorionic gonadotrophin (hCG; Chorulon, Intervet) 46–48 h
after PMSG and placed with a male for mating. Female mice were assessed
for the presence of a vaginal plug. If one was present, the embryonic age
was classiﬁed as E0.5 (Edwards et al., 2016). Two-cell embryos were
ﬂushed from oviducts with M2 (Sigma, Oakville, ON) 46–48 h post hCG
injection, washed, and placed into culture in KSOM (KSOMaa Evolve®,
Zenith Biotech, Guilford, CT, USA) at 37°C in a 5% O2, 5% CO2 and 90%
N2 atmosphere (Edwards et al., 2016).

Ethical approval
Animal care and handling was according to the guidelines of the Western
University Animal Care Committee approved by the Canadian Council on
Animal Care (Protocol number Watson 2010-021).

Effects of AMPK activator (AICAR) on
embryo development, diameter and cell
count
Mice were superovulated as described above. Two-cell embryos were cultured to the blastocyst stage and collected at 96 h post hCG injection.
Initially, embryos were cultured between concentrations of 0–2000 μM of

AICAR (Sigma) diluted from a 25 mM stock solution in KSOM. Embryos
were evaluated for development to the blastocyst stage at 96 h after hCG
(48 h culture from 2-cell). Further experiments were carried out with the
selected optimal dose of 1000 μM AICAR. Photomicrographs were taken
using a Leica microscope for measurement of embryo diameter. Embryos
were then either ﬁxed using 2% paraformaldehyde and stored until later
use for confocal microscopy or frozen at −80°C for later RNA analysis. To
determine total cell number DAPI-stained nuclei were counted on every
5 μM as z-stacks through each embryo. Two other known AMPK activators, metformin 0–1000 μM and phenformin 0–25 μM were tested to
investigate the consistency of outcomes.
Dose response experiments with the AMPK inhibitor Compound C
(CC, P5499, Sigma) were done in MF-1 mice (Harlan, Indianapolis, IN) in
EmbryoMax KSOM medium from EMD Millipore (Billerica, MA) in 2-cell
embryos treated for 48 h. CC was stored as a 10 mM stock solution in
DMSO. Later experiments used a dosage of 10 and 20 μM CC only or in
combination with 1000 μM AICAR (embryos were pretreated with CC
only for 3 h) in our standard culture conditions with CD-1 mice. Two cell
embryos were cultured for 48 h and examined for blastocyst development
and stored in radioimmunoprecipitation assay buffer (RIPA, 150 mM NaCl,
1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris) for
Western blot experiments as detailed below.

Whole-mount immunoﬂuorescent confocal
microscopy
For immunoﬂuorescent microscopy, embryos were ﬁxed in 2% paraformaldehyde in phosphate buffered saline (PBS) for 20 min at room temperature and stored in PHEM (60 mM PIPES, 25 mM HEPES, 10 mM
EGTA, 1 mM MgCl2-6 H2O) buffer at 4°C. For immunostaining, ﬁxed
embryos were permeabilized and blocked in 5% donkey serum
(Cedarlane, Burlington, ON) + 0.01% Triton X-100 in PBS for 1 h at room
temperature (Madan et al., 2007). All other steps were performed in antibody dilution buffer (0.5% donkey serum + 0.005% Triton X-100) in PBS.
Embryos were then incubated overnight at 4°C in the following primary
antibodies at the indicated dilutions: rabbit anti-CDX2 (ab76541, 1:100,
Abcam, Cambridge, MA, USA), rabbit anti-phospho-AMPK (07–681, 1:75,
Millipore, Temecula, CA), rat anti-ZO1 (MABT11, 1:100, Millipore,
Temecula, CA), rat anti-AQP9 (AQP91-A, 1:100, Alpha Diagnostic
International, San Antonio, TX), mouse anti-CDH1 (C20820, 1:100, BD
Transduction Laboratories, San Jose CA). Embryos were then incubated in
the following secondary antibodies at a 1:200 dilution: donkey anti-rabbit
(711-095-152), donkey anti-rat (712-095-153) or donkey anti-mouse
(715-095-151, CDH1) conjugated to FITC (Jackson ImmunoResearch,
West Grove, PA, USA). Embryos were counterstained with rhodaminephalloidin to stain ﬁlamentous actin and DAPI to stain DNA (Sigma
Aldrich, Canada) (Madan et al., 2007). Negative control embryos were not
exposed to primary antibody. Embryos were examined by laser-scanning
confocal microscopy (Olympus FV1000, Olympus Canada Inc., Markham,
ON). Z-stack slices were taken every 5 μM through each embryo to count
blue DAPI-stained cell nuclei.

RNA isolation, reverse transcription and
real-time PCR
Total RNA was extracted from similarly sized pools of frozen embryos
using a Picopure kit according to manufacturer’s instructions (Arcturus,
Mountain View, CA, USA). Samples were spiked with exogenous control
Luciferase mRNA (Promega Corporation, Madison, WI, USA) at
0.025 pg/embryo prior to extraction (Fong et al., 2007). Removal of genomic DNA was performed with a DNAse I digestion step (Qiagen,
Mississauga, ON). Following extraction, the eluted volume was 11 μl. RNA
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AMPK, AICAR (1 mM) and metformin (25 μg/ml, 151 μM), improved
development of mouse embryos cultured in inhibitory conditions (Eng
et al., 2007). AICAR (250 μM) improved meiotic competence in
oocytes of diabetic mice in which AMPK activity is decreased
(Ratchford et al., 2007). Metformin (25 μg/ml) treatment increased
phosphorylation of AMPK and reduced apoptosis in blastocysts of
obese mice (Louden et al., 2014). In contrast, exposure to 10 μM metformin caused early bovine embryos to arrest (Pikiou et al., 2013). In
summary, experimental evidence suggests that AMPK activity must be
regulated within narrow limits to achieve optimal preimplantation
embryo development.
The purpose of our study was to characterize the impact of AICAR
treatment and thus AMPK activation on preimplantation development
in the mouse. We investigated effects on development and to protein
and mRNA levels of several blastocyst formation gene families and
markers of embryonic developmental competence. We also assessed
the effects of AMPK activation on TE tight junction function and permeability. Prolonged AICAR treatment leads to loss of cell-to-cell contacts, loss of membrane ZO-1 staining, and nuclear condensation.
Embryos treated with AICAR had decreased transcript levels of several blastocyst formation gene family members. Blastocysts treated
with AICAR for only 9 h begin to collapse and in many, this developmental defect was irreversible. These results establish a foundation for
investigating the roles of AMPK during early development and its contribution to regulating early embryo developmental competence and
blastocyst formation. These outcomes are especially important due to
the increased use of metformin to treat PCOS in humans, as systemic
metformin may impact AMPK activity and blastocyst formation in early
embryos from treated women.
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Western blots
Western blots were carried out according to protocols developed by
Edwards et al. (2016). Thirty control or 1000 μM AICAR treated embryos
after 48 h of culture from the two cell stage were stored in RIPA buffer at
−80°C until use. Total protein lysates were resolved on a 4–12% Bis-Tris
gel (Life Technologies) and transferred to a polyvinylidene diﬂuoride
(PVDF) membrane. Membranes were cut into three pieces, above
100 kDa, 50–100 kDa and below 50 kDa. Membranes were blocked in 5%
skimmed milk or 5% bovine serum albumin in Tris-buffered saline-Tween
20 (TBS-T) for 1 h at room temperature, followed by overnight incubation
in primary antibody at 4°C. Membranes were then incubated in secondary
antibody goat anti-rabbit-horseradish peroxidase (HRP) (Cell Signaling
7074, Danvers, MA) for 1 h at room temperature. A mouse monoclonal
antibody against β-actin conjugated to HRP (A3854, Sigma, 1:20 000), was
used as a protein loading control. Membranes were visualized by detection
of Forte ECL (EMD Millipore, Billerica, MA). Densitometry analysis was
performed in Image Lab 4.0 (Bio-Rad). Primary antibodies used: antiCDX2 (Abcam, Cambridge, MA, ab76541,1:500), anti-phospho-AMPKα
(Thr172) (EMD Millipore 07–681, 1:500), anti-AMPKα (Cell Signaling
5831, 1:500), anti-phospho-ACC (ser79, Cell Signaling 3661, 1:250), antiACC (Cell Signaling 3676, 1:1000) anti-E-cadherin (BD Transduction
Laboratories C20820, 1:500). Phospho-ribosomal protein S6 (ser235/
236, Cell Signaling 4858) was detected as part of the PathScan multiple
protein cocktail (CS 5301).

Embryo recovery from AICAR treatment:
embryo development, diameter and cell
counts
Mice were superovulated as described above. Two-cell embryos were
ﬂushed from oviducts with M2 on E1.5, washed with KSOMaa, and placed
into culture at 37°C in 5% CO2, 5% O2 and 90% N2 atmosphere for 48 h.
Embryos that had formed blastocysts were separated, washed and placed
into culture with either 0 or 1000 μM AICAR for 9 h. Blastocyst morphology and cavity volume were assessed and recorded on photomicrographs taken with a Leica microscope. Embryos were then washed in

KSOMaa Evolve. AICAR-treated embryos were separated into those that:
(1) remained a blastocyst or (2) those that collapsed (i.e. 75% or greater
reduction in blastocyst cavity) for an additional 24 h in drug free culture
medium to assess recovery rates. The percentage of blastocysts with fully
expanded blastocyst cavities at 24 h of recovery time was measured.
Photomicrographs were again taken for measurement of embryo diameter. Embryos were then ﬁxed or frozen for real-time PCR studies as
described above.

Quantiﬁcation of CDX2 and F-actin staining
Embryos were stained and mounted on slides as described above.
Microscopic images were obtained using a confocal microscope (Olympus) at
a magniﬁcation of 40×, converted to tiff ﬁles and ﬂuorescence intensity was
measured using ImageJ software (National Institutes of Health, Bethesda,
MD, USA). The oval tool was used to draw a record of interest (ROI) around
the blastocyst. For CDX2, background was calculated from the mean of ROI
of the negative controls (no primary antibody) and was subtracted from the
ROI of the control and AICAR treated embryos. F-actin was not adjusted for
background, as all groups had actin staining.

Measurement of tight junction permeability
by FITC-dextran uptake assay
Embryos were cultured from the two-cell stage to blastocysts in KSOM
Evolve. Blastocysts were sorted into control and 1000 μM AICAR groups
and incubated for 9 h. For a positive control, blastocysts were placed
into culture with KSOM containing 2 mM EGTA (ethylene glycol Bis(β-aminoethyl ether) N,N,N,N tetraacetic acid) for 30 min to disrupt
adherens junctions (Violette et al., 2006; Bell and Watson, 2013). After incubation all treatment groups were placed into 20 μl drops of KSOM containing
1 mg/ml 40 kDa FITC-Dextran (Sigma) for 30 min. Following this, blastocysts
from each group were washed separately three times in 50 μl wash drops
of KSOM and placed into a ﬁnal fresh KSOM drop for immediate morphological assessment using a Leica compound ﬂuorescent microscope equipped
with a camera.

ATP assay
A Luminescent ATP Detection Assay kit (ab113849, Abcam) was used to
measure total blastocyst ATP with the following modiﬁcations made from
the manufacturer’s protocol according to Edwards et al. (2016). ATP standards between 0.78125 pM and 100 pM were diluted in water and added
in a volume of 10 –100 μl KSOM. Five control and 48 h AICAR-treated
embryos were placed into a volume of 100 μl KSOM in wells of a 96-well
plate. Wells containing KSOM only were blank controls. Luminescence
read on a Spectromax M5 plate reader (Molecular Devices, Sunnyvale,
CA) at 450 nm. A standard curve was generated with the luminescence
detected minus the average of the blank controls. Control or AICAR samples minus blanks were calculated from the standard curve. Data were
analyzed using SoftMax Pro software (Molecular Devices).

Statistical analysis
A one-way ANOVA was performed for developmental frequencies (%) of
two-cell embryos treated with various doses of AICAR, CC, metformin or
phenformin. A Holm-Sidak test was used to test for differences among
means. T-tests were used to test for differences in diameters and cell numbers between control and 1000 μM AICAR-treated embryos, as well as
ATP concentrations. A Mann–Whitney U statistic was used to determine
differences between blastocysts that were not treated or treated with
AICAR for 9 h. The data was not normally distributed because all control
embryos remained at the blastocyst stage while some AICAR-treated
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samples were reverse transcribed (RT) with Sensicript (Qiagen) in a mix
containing 2 μl 10× buffer, 1 μl 10 mM dNTPs, 2 μl 10 μM anchored
oligodT23 (1 μM ﬁnal concentration, Sigma) and 1 μl 10 μM random nonamers (0.5 μM ﬁnal concentration, Sigma), 1 μl 10 U/μl RNAse inhibitor
(Life Technologies, Burlington, ON) and 1 μl Sensiscript in a volume of
20 μl. The reaction was carried out for 10 min at 25°C, followed by 90 min
at 37°C in a thermocycler.
For real-time qPCR, we used the external (Luciferase) control for quantiﬁcation (Fong et al., 2007). PCR was performed in a Bio-Rad CFX384
Real-time system (Bio-Rad, Mississauga, ON) using TaqMan® Gene
Expression Assays (Applied Biosystems, Foster City, CA, USA). A custom
Taqman® primer and probe set for Luciferase were designed using the
Applied Biosystems Assays-by-Design File Builder program (Fong et al.,
2007). Commercially available TaqMan® Gene Expression Assays for Cdx2
(caudal homeobox domain 2, Mm01212880_m1), Cdh1 (E-cadherin,
Mm00486918_m1), Aqp9 (aquaporin 9, Mm00508094_m1), Ocln (occludin,
Mm00500912_m1), Tjp1 (tight junction protein 1, ZO1, Mm00493699_m1),
Actb (beta actin, Mm01205647_g1), Gadd45a (growth arrest and DNA
damage-inducible 45 alpha, Mm00432802_m1), Atp1b1 (Na+/K+ ATPase
β1 subunit, Mm00437612_m1) and Atp1a1 (Na+/K+ ATPase α1 subunit,
Mm00523255_m1) were used to assess effects to mRNA transcript relative
levels. Standard cycling conditions were 50° for 2 min, 95° for 5 min, followed
by 50 cycles of 95° for 15 s and 60° for 1 min.
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Results
AICAR treatment caused an inhibition
of preimplantation development
AICAR treatment caused a dose-dependent inhibition in embryo
development. Signiﬁcantly fewer two-cell embryos developed to the
blastocyst stage after 48 h of culture at a concentration of 500, 1000
and 2000 μM AICAR (45.9, 26.6 and 9.4% blastocyst development,
respectively, Fig. 1A). Development of 0, 10 and 100 μM AICARtreated embryos did not vary signiﬁcantly from one another and
resulted in blastocyst developmental frequencies of 65–80%. Thus, the
1000 μM dose of AICAR was selected as an optimal dose for all further experiments. Blastocyst total cell number was signiﬁcantly lower
after 48 h of 1000 μM AICAR treatment (Fig. 1B). Most AICAR-treated
embryos arrested at the morula stage. Additionally, embryo diameter
was signiﬁcantly reduced after 48 h AICAR treatment (Fig. 1C). Two
other known AMPK activators, metformin (Supplementary Fig. S1A)
and phenformin (Supplementary Fig. S1B) displayed signiﬁcant dosedependent negative effects on embryo development as well.
We also investigated the effects of treatment with a commonly used
inhibitor of the AMPK pathway, Compound C (CC). In our hands,
embryo development was not detectably inhibited until higher
(100 μM, Supplementary Fig. S1C) than normally used concentrations
(10 μM), but even this decrease was not statistically signiﬁcant. The
100 μM dose however did have a signiﬁcant effect on embryo diameter
(data not shown). When treated with 10 and 20 μM CC, embryo
development was not affected and the effects of AICAR were not
reversed when treated in combination (Supplementary Fig. S1D).

AICAR treatment increased phosphorylated
AMPK and decreased blastocyst formation
proteins

Figure 1 AICAR treatment at the 2-cell stage decreased development, blastocyst diameter and total cell counts. (A) Development to
blastocyst after treatment with various doses of AICAR, n = 5,
133–148 embryos per dose. a,b,c,d Groups without letters in common are signiﬁcantly different, P < 0.001. (B) Cell counts after culture
for 48 h with 0 or 1000 μM AICAR, n = 5, with 92 embryos for control and 65 AICAR-treated embryos. ***P < 0.001. (C) Embryo diameter after culture for 48 h with 0 or 1000 μM AICAR, n = 9, with 317
for control and 333 for AICAR-treated embryos. ***P < 0.001.

AICAR potently stimulated the ﬂuorescence intensity of phosphorylated AMPK (p-AMPK; Fig. 2A). Embryos treated with AICAR for 48 h
displayed a staining pattern of zona occludens-1 (ZO-1, TJP1) that varied dramatically from that of control embryos. In controls, ZO1 was
present at cell borders and co-localized with actin (yellow staining in
merged channel, Fig. 2B) while ZO1 was predominantly cytoplasmic in
AICAR-treated embryos. AQP9 ﬂuorescence intensity was also
decreased at the cell membranes in AICAR-treated embryos (Fig. 3A).
In contrast, no obvious effect to E-cadherin (E-cad, CDH1) staining

was observed (Fig. 3B). E-cadherin maintained its normal localization
to surrounding cell borders in AICAR-treated embryos (Fig. 3B). FActin (red staining) however, was often decreased after AICAR treatment (Figs. 2A, B and 3 A, B). Some embryos displayed cell rounding
and apparent loss of cell-to-cell contacts (arrowheads, Fig. 2A). In addition, some AICAR-treated embryos showed signs of nuclear condensation, (arrows, Fig. 2A), which is a common early sign of apoptosis.
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embryos collapsed. The data is reported as the median percentage. When
we examined embryos after 24 h recovery, a non-parametric Rank
ANOVA was used due to unequal variation since controls remained all
blastocysts. A Tukey test was used for multiple comparisons. For qRTPCR samples, quantiﬁcation was normalized to the exogenous control luciferase RNA levels. Expression levels were calculated according to the
method of Pfafﬂ (2001), where expression level is calculated as the ratio
between EtargetΔCT(target gene)/ELucΔCT(Luc). E = Efﬁciency of the primer
set, which was calculated by the slope of 10-fold dilutions of a standard
sample according to the formula of E = 10(−1/slope). The ΔCT value =
CT(avg of control) – CT(each sample). Statistical analysis was performed
using SigmaStat® 3.5 (Jandel Scientiﬁc Software, San Rafael, CA, USA) software package. Real-time qRT-PCR results are presented as the mean ±
standard error of the mean (SEM).
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Effects of AICAR Treatment on protein
detection by western immunoblotting
AICAR treatment from the 2-cell stage signiﬁcantly increased phosphorylated AMPK nearly 7-fold (Fig. 4A). CDX2 protein signiﬁcantly
decreased 4-fold in AICAR-treated embryos (Fig. 4B). However, Ecadherin protein (CDH1) was not affected by AICAR treatment
(Fig. 4C). Uncropped blots are shown in Supplementary Fig. S2. In a
preliminary analysis, we observed that AICAR tended to increase
phosphorylation of ACC and decreased pS6 (Supplementary Fig. S3).
However, pre-treatment with CC for 3 h prior to AICAR treatment
did not alter phosphorylation of AMPK and ACC (Supplementary
Fig. S4) and did not reverse the AICAR-stimulated pS6 decrease.

AICAR treatment decreased the expression
of key blastocyst formation genes
When embryos were treated from the two-cell stage with 1000 μM
AICAR, relative mRNA transcript levels encoding several blastocyst

formation gene families were affected. Cdx2, Aqp9 and Atp1b1 mRNA
levels were detected at signiﬁcantly lower levels in AICAR-treated
embryos, while Gadd45a mRNA was increased (Fig. 5). Levels of Ocln,
Cdh1, Atp1a1, Actb and Tjp1 mRNA were not signiﬁcantly affected
(Fig. 5).

AICAR treatment at the blastocyst stage
caused some embryos to collapse and
treatment was only partly reversible
About 23% blastocysts collapsed after incubation in 1000 μM AICAR
for 9 h. All non-treated embryos remained at the blastocyst stage,
while the median value of AICAR-treated embryos remaining blastocysts was 76.92%. After 9 h of incubation, control embryos were
either frozen at −80°C or washed three times (sham control) and
placed back into culture for an additional 24 h in drug free KSOM.
AICAR-treated embryos were either frozen or washed three times in
AICAR-free KSOM and separated into two drug free KSOM groups
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Figure 2 AICAR treatment increased detection of p-AMPK and decreased ZO1 (TJP1) localization to the cell membrane. (A) phospho-AMPK after
48 h culture of 2-cell embryos. Green panel shows p-AMPK ﬂuorescence. Red is rhodamine-phalloidin staining of F-actin. Blue is DAPI-stained DNA.
Merged ﬁgure shows color overlap. Arrowheads show evidence of loss of cell-to-cell contacts. Arrows show examples of condensed nuclei. Scale bar
demonstrates 50 μM. Inset shows negative control with no primary antibody. (B) ZO1 (TJP1) after 48 h culture of 2-cell embryos. Green panel shows
ZO1 ﬂuorescence. Red is rhodamine-phalloidin staining of F-actin. Blue is DAPI-stained DNA. Yellow demonstrates overlap of ZO-1 and actin in the
merged ﬁgure of the control embryos, which is missing in the AICAR-treated embryos. Scale bar demonstrates 50 μM. Inset shows negative control
with no primary antibody.
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according to their phenotype after 9 h of AICAR treatment: (1) blastocysts maintaining a cavity and (2) collapsed blastocysts. Examples of
AICAR-treated embryos that collapsed are shown (asterisks, Fig. 6B).
After 24 h of recovery culture, all control blastocysts remained blastocysts with a cavity. The median value of AICAR-treated embryos that
initially had a cavity and maintained the cavity was 84.62%, and the
median value of AICAR-treated embryos that had collapsed and
recovered to generate a cavity was 56.67%. Embryo diameters were
measured at the 0 , 9 and 24 h of recovery time points (Fig. 6A). At
9 h, the AICAR-treated group had signiﬁcantly smaller diameters than
controls at 9 h (61.26 ± 0.92 versus 76.05 ± 1.27 μM, P < 0.05).
After 24 h of recovery culture, controls expanded up to an average of
103.90 ± 2.16 μM and were signiﬁcantly different from all other
groups. Following 24 h of washout of AICAR, embryos that remained
blastocysts after 9 h of AICAR treatment (aibl) and those that initially
collapsed but recovered to blastocyst after 24 h (ai rec) had similar
diameters, 67.98 ± 2.15 and 72.43 ± 0.66 μM, respectively. Aicoll

were embryos that collapsed after 9 h AICAR treatment and never
recovered, and were signiﬁcantly smaller (53.19 ± 0.62 μM) than
either aibl or ai rec blastocysts. Representative photomicrographs
from 9 and 24 h periods are shown in Fig. 6B. After 24 h of recovery,
embryos were frozen for further analysis as pools of those that (1)
maintained a blastocyst cavity throughout (aibl); (2) those that initially
collapsed but recovered to become expanded blastocysts (ai rec);
and (3) those that remained collapsed (aicoll) and showed no recovery from treatment.

CDX2 protein levels are signiﬁcantly reduced
in AICAR treated embryos
CDX2 immunoﬂuorescence intensity decreased after 1000 μM
AICAR treatment (Fig. 7A amd B), while F-actin ﬂuorescence intensity
was not signiﬁcantly lower in AICAR treated embryos compared to
control embryos (Fig. 7C).
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Figure 3 AICAR treatment decreased AQP9 but did not affect E-cadherin (CDH1) protein. (A) Aquaporin 9 (AQP9) after 48 h culture of 2-cell
embryos. Green panel shows AQP9 ﬂuorescence. Red is rhodamine-phalloidin staining of F-actin. Blue is DAPI-stained DNA. Merged ﬁgure shows color overlap, there is less overlap of AQP9 and actin in AICAR-treated compared to control embryos. Scale bar demonstrates 50 μM. Inset shows negative control with no primary antibody. (B) E-cadherin (CDH1) after 48 h culture of 2-cell embryos. Green panel shows CDH1 ﬂuorescence. Red is
rhodamine-phalloidin staining of F-actin. Blue is DAPI-stained DNA. Yellow demonstrates overlap of CDH1 and actin in the merged ﬁgure. There is a
similar extent of overlap in both control embryos and AICAR-treated embryos. Scale bar demonstrates 50 μM. Inset shows negative control with no
primary antibody.
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02, 03) and AICAR-treated (A1, A2, A3) embryos. β-actin shows equal protein loading, not signiﬁcantly different between control and AICAR-treated
embryos. (A) p-AMPK after 48 h culture of 2-cell embryos. There was n = 3 independent sample pools (30 embryos per pool). Control (01, 02, 03)
and AICAR-treated (A1, A2, A3) embryos were signiﬁcantly different, *P < 0.05. (B) CDX2 after 48 h culture of 2-cell embryos. Control (01, 02, 03)
and AICAR-treated (A1, A2, A3) embryos were signiﬁcantly different, **P < 0.01. (C) CDH1 after 48 h culture of 2-cell embryos. Control (01, 02, 03) and
AICAR-treated (A1, A2, A3) embryos were not signiﬁcantly different.

AICAR treatment of blastocysts caused
a reduction of some blastocyst formation
gene mRNA levels
Due to the much larger diameter of the 24 h control (Con 24)
embryos, we analyzed relative mRNA levels only among: (1) 0 h controls, (2) 9 h of treatment and (3) 24 h of recovery after AICAR treatment groups. Cdx2 abundance increased from time 0 to 9 h in
controls, but was signiﬁcantly decreased in 9 h AICAR-treated
embryos (Fig. 8). Even after 24 h of recovery time, Cdx2 mRNA levels
in AICAR-treated blastocysts (aibl and ai rec) had not recovered to
Con 9 h levels. Embryos that remained collapsed (aicoll) did not show
any recovery in Cdx2 mRNA levels. Like Cdx2, Cdh1 was highest in
Con 9 h. AICAR-treated embryos treated for 9 h had signiﬁcantly lower Cdh1 mRNA than Con 9 h embryos. However, after 24 h of recovery, AICAR-treated embryos that were blastocysts (aibl and ai rec)
had similar levels of Cdh1 transcript abundance as Con 9 h, while aicoll
embryos did not. The aicoll group had the lowest level of Aqp9
mRNA. Atp1b1 mRNA levels increased from time 0 in Con 9 h
embryos that continued to expand, while AICAR 9 h embryos had signiﬁcantly lower Atp1b1 mRNA levels than Con 9 h. After 24 h of
recovery, aibl and ai rec blastocysts displayed a modest increase in
Atp1b1 mRNA levels while embryos in the aicoll group did not. Only
the aicoll group embryos contained signiﬁcantly lower Ocln levels than
Con 9 h expanded blastocysts. Tjp1, Gadd45a, Actb and Atp1a1
mRNA levels did not signiﬁcantly differ between times, treatments and
stages. This outcome is signiﬁcant as while the aicoll group overall

showed very limited if any recovery from treatment, it was possible to
detect mRNA from these embryos for the blastocyst formation gene
family members. Thus, while these embryos did not recover from
treatment, they were still intact.

AICAR treatment caused embryos
to become more permeable in a tight
junction permeability assay
Blastocysts incubated in AICAR for 9 h displayed a signiﬁcant 2.8-fold
increase in permeability to 40 kDa FITC-Dextran (50.3 ± 0.5%).
Control embryos were the least permeable (18.1 ± 5.3%), while positive control EGTA-treated embryos were intermediate (30.7 ± 6.5%,
Fig. 9A). Representative bright-ﬁeld and FITC-ﬁlter images are shown
in Fig. 9B.

AICAR treatment did not affect total
embryo ATP content
There were no signiﬁcant differences in total ATP content
between control embryos or those treated with AICAR for 48 h
(data not shown).

Discussion
Applying 1000 μm AICAR, an AMPK activator, to mouse 2-cell
embryos reduced the number of embryos that developed to the
blastocyst stage at 48 h. This was conﬁrmed with other known
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Figure 4 AICAR treatment increased detection of p-AMPK and decreased CDX2 by Western blot. Top panel shows Western blots, Control (01,
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activators of AMPK, metformin and phenformin. The effective dose of
metformin in our study was 1000 μM, similar to that used in other
studies in tissues as well as oocytes and embryos (0.5–2 mM, Zhou
et al., 2001; Meley et al., 2006; Bilodeau-Goeseels et al., 2011, 2014;
Bolnick et al., 2016). Similarly, metformin inhibited mouse blastocyst
development at 100 μg/ml (~600 μM) in an earlier study (Bedaiwy
et al., 2001). Maximal blood concentrations in diabetic humans treated
with metformin are recommended to be lower than 2.5 mg/l (19 μM,
Graham et al., 2011). In a study performed in mice, maximal serum
concentrations of metformin were 52 μM after an oral dose of 50 mg/kg,
but accumulated at higher concentrations in some tissues (Wilcock
and Bailey, 1994). In our study, phenformin had a greater effect than
metformin on embryo development, in accordance with similar studies
with mid-gestation mouse embryos (Denno and Sadler, 1994) and
killed preimplantion embryos at doses above 100 μM. Diminishing
doses blocked mouse embryo development at later stages. In our
study, the minimum effective dose of phenformin for blocking blastocyst formation was 10 μM. AICAR reduced the embryo diameter as
well as embryo cell number. This concentration (1000 μM) was similar

to doses of AICAR that stimulate meiosis in mouse oocytes (Downs
et al., 2002) and those used to activate AMPK in other studies (Mayes
et al., 2007; Yokoyama et al., 2011; Ding et al., 2013; Xie et al., 2013).
Treated embryos in our study arrested primarily at the morula stage.
Activation of AMPK induces cell-cycle arrest in some cancer cell lines
(reviewed in Hardie, 2011). AICAR treatment of blastocysts frequently resulted in blastocyst collapse, blastomere rounding and loss
of cell-to-cell contacts. Furthermore, embryos treated from the twocell stage onwards displayed nuclei that were condensed, suggestive of
initiation of apoptosis seen in other cell types after AMPK activation
(Okoshi et al., 2008). Confocal microscopy and Western blot analysis
demonstrated that AICAR potently stimulated phosphorylation of
AMPK. Western blot analysis showed that AICAR tended to increase
phosphorylation of ACC and decrease pS6 levels. AICAR and metformin treatment have been shown to decrease pS6 previously (Tosca
et al., 2007; Guo et al., 2009).
We found that the AMPK inhibitor, CC, did not inhibit blastocyst
development at normally used concentrations (5–10 μM, Chen et al.,
2006; Bilodeau-Goeseels et al., 2011, 2014; Xie et al., 2013) and only
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Figure 5 Real-time PCR analysis of mRNA levels of 2-cell embryos cultured for 48 h with AICAR. Cdx2, Cdh1, Aqp9, Atp1b1, Atp1a1, Actb, Tjp1,
Ocln and Gadd45a are shown. Signiﬁcant differences between control and AICAR-treated embryos are signiﬁed by *P < 0.05. Mean ± SEM are
depicted. There was n = 3–5 independent samples.

780

Calder et al.

became inhibitory at 100 μM. CC did not reverse the inhibitory effect
of AICAR treatment on development, or on phosphorylation of
AMPKα and acetyl CoA carboxylase (pACC), nor block the decrease
in pS6. Previous studies have shown a reduction in pACC in hepatocytes (Zhou et al., 2001) and in mouse oocytes following CC treatment (Chen et al., 2006). However, AICAR reduced oocyte
maturation yet failed to increase pAMPK in bovine oocytes (BilodeauGoeseels et al., 2011) or to increase pACC in bovine and porcine
oocytes (Bilodeau-Goeseels et al., 2011, 2014). In addition, CC did
not affect pACC in porcine oocytes (Bilodeau-Goeseels et al., 2014)
and CC failed to block pAMPK and pACC in another study (Meley
et al., 2006), which was dependent on culture conditions. Further, in a
study by Guo et al. (2009), CC was able to block the effects of AICAR

on pACC but did not appear to block AICAR-mediated reduction in
phosphorylation of pS6. Metformin treatment also reduces S6 phosphorylation and this was not blocked by CC or AMPK siRNA knockdown (Klubo-Gwiezdzinska et al., 2012). This may demonstrate that
both AICAR and CC may affect embryo development by AMPKdependent and AMPK-independent mechanisms.
Messenger RNA was decreased for both Atp1b1 and Aqp9 following
AICAR treatment, which are both required for expansion of the
blastocyst (Barcroft et al., 2003; Madan et al., 2007). AICAR treatment
decreased Aqp9 mRNA levels over 12 h in a previous study
(Yokoyama et al., 2011). Embryos treated with AICAR from the twocell stage had reduced Aqp9 mRNA and decreased AQP9 ﬂuorescence intensity at the cell membrane. Atp1b1 mRNA was signiﬁcantly
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Figure 6 Recovery of Blastocysts following 9 h of AICAR Treatment. (A) Embryo diameter at time 0, 9 h of treatment or 24 h of recovery. n = 5–8
with 96–563 embryos per group. a,b,c,d,e Groups that do not have a letter in common are signiﬁcantly different, P < 0.05. (B) A photomicrograph of
control or AICAR-treated embryos of one experiment is representatively shown after 9 h treatment and then after 24 h of recovery in drug free
medium (Con 24 h and ai 24 h). At 9 h, AICAR embryos were divided into those that remained blastocysts and those that collapsed. AICAR-treated
embryos are darker and less expanded than controls. Examples of collapsed embryos are shown with red asterisks. Scale bar demonstrates 50 μM.
Time 0, (control at start of experiment); Con 9 h, untreated controls cultured for 9 h; AICAR 9 h, (blastocysts treated with AICAR for 9 h); Con 24 h,
(controls cultured for 24 h in drug free medium); aibl 24 h, (AICAR treated embryos that did not collapse after 9 h treatment); ai rec 24 h, (AICAR
treated embryos which initially collapsed that did recover after 24 h in drug free medium); aicoll 24 h, (AICAR treated collapsed blastocysts that did
not recover after 24 h in drug free medium).
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panel shows CDX2 ﬂuorescence. Red is rhodamine-phalloidin staining of F-actin. Blue is DAPI-stained DNA. Merged ﬁgure shows color overlap. CDX2 is conﬁned
to the nuclei of TE in control embryos. (B) Quantiﬁcation of CDX2 staining in relative ﬂuorescence units, n = 3 with a total of 49 and 50 embryos. CDX2 protein
is lower in AICAR-treated embryos, P < 0.05. (C) Quantiﬁcation of F-actin staining in relative ﬂuorescent units, n = 3 with a total of 49 and 50 embryos. F-actin
intensity is not different between control and AICAR-treated embryos. Scale bar demonstrates 50 μM. Inset shows negative control with no primary antibody.

lower in embryos treated continuously from the two-cell stage and in
blastocysts treated for only 9 h. Blastocysts which recovered from
AICAR treatment regained Atp1b1 expression while those that
remained collapsed did not. Interestingly, Atp1a1 mRNA was not signiﬁcantly decreased by AICAR treatment. This may be related to the
fact that Atp1a1 knockout embryos (Barcroft et al., 2004) can become
blastocysts while Atp1b1 knockout embryos cannot (Madan et al.,
2007). This suggests that the β-1 subunit of Na+/K+ ATPase may be
the more critical partner, serving as a rate limiting step for successful
cavitation. Studies have demonstrated that Atp1a1 levels are substantial during mouse preimplantation development and are thus not likely
rate limiting with regards to providing appropriate Na+/K+ -ATPase
activity to fuel blastocyst formation (Watson et al., 1990; Barcroft
et al., 2004). It is also possible that the reduced Atp1b1 mRNA translated to reduced protein expression in the TE, which is also required
for normal tight junction formation.
TJP1, OCLN and CDH1 are all key proteins that collaborate
together in the mechanisms controlling tight junction formation and
establishment of the blastocyst. Fluorescence intensity of tight junction
protein (TJP1, ZO-1) was decreased at the membrane in AICARtreated embryos though it was not affected at the mRNA level. Ocln
mRNA decreased after AICAR treatment, and was signiﬁcantly
decreased in blastocysts that collapsed after recovery in drug-free
medium. We have previously reported decreased ZO1 and occludin
protein in ouabain (Na+/K+ ATPase inhibitor and possible ligand)

treated embryos (Violette et al., 2006). AICAR-treated blastocysts
had increased uptake of FITC-labeled dextran compared to controls,
which indicates that tight junctional permeability increased in treated
embryos. About 50% of AICAR-treated embryos were permeable to
40 kDa FITC-Dextran compared to 18% of untreated controls. The
consequences would be that AICAR-treated embryos would have
more difﬁculty in maintaining an expanded blastocyst cavity and in fact
would be unlikely to cavitate if the deﬁcit persisted, as we observed.
Blastocyst cavity formation relies on a TE tight junctional seal forming
to prevent trapped blastocyst ﬂuid from leaking out from between TE
cells resulting in blastocyst collapse (Watson and Kidder, 1988; Betts
et al., 1998; MacPhee et al., 2000; Watson et al., 2004). Although
AMPK activation increases tight junction assembly in some epithelial
cells and decreases paracellular permeability (Zhang et al., 2006;
Zheng and Cantley, 2007), by contrast, activation of AMPK can also
increase tight junction width and paracellular permeability in salivary
cells (Ding et al., 2013).
E-cadherin was not affected at either the mRNA or protein level in
AICAR treated embryos. Cdh1 mRNA did however decrease in blastocysts treated for 9 h with AICAR and remained low in embryos that
remained collapsed. F-actin ﬂuorescence was visibly decreased at cell
cortical regions although no change in the level of Actb mRNA or protein was observed in AICAR treated embryos. F-actin results from the
polymerization of any of three types of actin; alpha, beta or gamma.
AMPK activation can decrease actin assembly in endothelial cells
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Figure 7 AICAR treatment of blastocysts decreased immunoﬂuorescent detection of CDX2 protein. (A) CDX2 after 48 h culture of 2-cell embryos. Green
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(Blume et al., 2007) and mesenchymal cancers displayed decreased Factin after AMPK activation along with decreased markers of invasiveness (Chou et al., 2014).
CDX2 is an important transcription factor and marker for TE cell
fate determination and TE differentiation. CDX2 protein was signiﬁcantly decreased in AICAR-treated blastocysts, as well as at the
mRNA level in both experiments. Reduced CDX2 protein was previously seen in embryos and trophectoderm stem cells treated with
AICAR or subjected to hyperosmolar stress (Xie et al., 2013). Bovine
embryos that resulted in pregnancy had higher expression of Cdx2
mRNA than those that did not result in pregnancy (El-Sayed et al.,
2006). Furthermore, mouse Cdx2 knockout embryos do not give rise
to live births (Chawengsaksophak et al., 1997). Collectively, a decline

in CDX2 expression following AICAR treatment is a strong indicator
of expected declining developmental competence.
AMPK increases expression of GADD45A in some cells (Chen
et al., 2015). Transcription of Gadd45a is stimulated by oxidative stress
and causes cell cycle arrest at G2/M phase (Furukawa-Hibi et al.,
2002). Thus, it may be responsible for halting embryonic cell proliferation. Gadd45a–/– mice are more susceptible to mammary tumors
and tumors had less expression of apoptosis and senescence markers
(Tront et al., 2006). In our experiments, Gadd45a mRNA was
increased in embryos treated 48 h from the two-cell stage but not in
blastocysts treated for a shorter time. This may suggest that after a
long period of AMPK activation, increased Gadd45a may lead some
embryos to become senescent.
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Figure 8 Real-time PCR analysis of blastocyst mRNA levels at time 0, 9 h of treatment or 24 h of recovery. Cdx2, Cdh1, Aqp9, Atp1b1, Atp1a1, Actb,
Tjp1, Ocln and Gadd45a are shown. Signiﬁcant differences between control and AICAR-treated embryos are signiﬁed by a,b,c,d P < 0.05. There were
n = 4 replicates. Time 0, (control at start of experiment); Con 9 h, untreated controls; AICAR 9 h, (blastocysts treated with AICAR for 9 h); Con 24 h,
(sham controls cultured for 24 h in drug free medium); aibl 24 h, (AICAR treated embryos that did not collapse after 9 h treatment after a further 24 h
in drug free medium); ai rec 24 h, (AICAR treated collapsed blastocyst that did recover after 24 h in drug free medium); aicoll 24 h, (AICAR treated collapsed blastocysts that did not recover after 24 h in drug free medium).
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Together, our results demonstrate that AMPK is likely a critical
regulatory nexus for ensuring that blastocyst formation unfolds as it
should. The outcomes also alert us to the possibility of residual downstream negative effects of metformin treatment on embryonic developmental competence. Further studies should investigate this
possibility to better inform fertility treatments and protocols using
metformin to treat PCOS and type II diabetes.
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